Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Inclusion Criteria: 1. HIV patients \>18 years old who provide signed and dated informed consent; 2. Males and females; 3. SOT recipients (heart, liver or kidney); 4. On stable antiretroviral therapy (ART) for ≥6 months preceding the screening visit; 5. Plasma HIV RNA \<50 cop/ml for 12 months (2 tests separated by at least 12 months with no viral load \>50 between determinations); 6. Absence of major reverse transcriptase or integrase gene mutations affecting study drug efficacy by proviral DNA sequencing Exclusion Criteria: 1. HIV patients who have stopped ART due to virological failure; 2. HIV patients who require treatment with DTG contraindicated medications; 3. History or presence of an allergy or intolerance to the study drug; 4. Active opportunistic infection; 5. Neoplasms requiring chemotherapy. 6. Pregnancy or breast feeding or planned pregnancy during the study period 7. Any other contraindication to study drugs.